Literature DB >> 26050352

Clinical significance of ASCUS and ASC-H cytological abnormalities: a six-year experience at a single center.

G S Demirtas, L Akman, O Demirtas, B S Hursitoglu, M C Terek, O Zekioglu, H Yilmaz, A A Ozsaran.   

Abstract

BACKGROUND: To evaluate colposcopic biopsy results of patients with cervical cytological findings of atypical squamous cells of undetermined significance (ASC-US) and atypical squamous cells with high-grade lesions that cannot be excluded (ASC-H).
MATERIALS AND METHODS: A retrospective evaluation of data from 358 patients, who had cervical cytological findings of ASC-US (n = 335) and ASC-H (n = 23), and had colposcopic assessments between 2005 and 2011.
RESULTS: Cervical biopsy results of patients diagnosed with ASC-US cytology (n = 335) revealed cervical squamous cell carcinoma 0.9 % (n = 3) at biopsy, cervical intraepithelial neoplasia 3 (CIN 3) in 3.8 % (n = 13), cervical intraepithelial neoplasia 2 (CIN 2) in 1.1 % (n = 4), cervical intraepithelial neoplasia 1 (CIN 1) in 35.2% (n = 118), and benign lesions in 59 % (n = 197). Cervical biopsy results of patients diagnosed with ASC-H cytology (n = 23) revealed CIN 3 at biopsy in 39.3% (n = 9), CIN 2 in 21.7% (n = 5), CIN 1 in 26% (n = 6), carcinoma in situ in 8.7% (n = 2), and squamous cell cancer in one patient (4.3%).
CONCLUSION: The cytological diagnosis of ASC-US may lead to the diagnosis of cervical intraepithelial lesion of higher grades as well as cervical cancer and should be evaluated by colposcopic cervical biopsy.

Entities:  

Mesh:

Year:  2015        PMID: 26050352

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  1 in total

1.  Retrospective analysis of cervical cancer and precancerous lesions in patients with atypical squamous cells of undetermined significance in China.

Authors:  Yan-Ying Wang; Ling-Hua Kong; Yang Liu; Shu Wang; Qing-Bo Fan; Lan Zhu; Jing-He Lang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.